SMO and neoplasm: This includes overexpression of HH ligand in tumor and tumor microenvironment (TME), loss of function mutation in PTCH1 and SUFU, GLI2 amplifications, and gain of function mutation in SMO [10,31,33,34,35,36,37,38,39].